On October 20, 2021 PTC (Nasdaq: PTC) reported that it will release its fiscal 2021 fourth quarter and full year results on Wednesday, November 3rd after the stock market closes. Senior management will host a live webcast and conference call to review the results on Wednesday, November 3rd at 5pm Eastern Time (Press release, PTC Therapeutics, OCT 20, 2021, View Source [SID1234591617]). The earnings press release, accompanying earnings presentation, and financial data tables will be accessible prior to the conference call and webcast on the Investor Relations section of the Company’s web site at PTC Investor Relations.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

What: PTC Fiscal Q4’21 Conference Call and Webcast

When: Wednesday, November 3rd, 2021 at 5:00pm (ET)

Webcast: View Source

Replay: To access the replay via webcast, please visit View Source.

Please note that statements made on the conference call and webcast are as of the date of the conference call and webcast and PTC does not assume any obligation to update any statements made live or the archived call. Matters discussed may include forward-looking statements about PTC’s anticipated financial results and growth, as well as about the development of products and markets, which are based on current plans and assumptions. Actual results in future periods may differ materially from current expectations due to a number of risks and uncertainties, including those described from time to time in reports filed by PTC with the U.S. Securities and Exchange Commission, including PTC’s most recent reports on Form 10-K and 10-Q.

On October 20, 2021 SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a clinical-stage biopharmaceutical company focused on developing life-changing medicines for patients with severe rare diseases and cancer, reported that it has entered into an exclusive worldwide license agreement with Dana-Farber Cancer Institute (Dana-Farber) and a sponsored research agreement (SRA) with Stanford Medicine for a portfolio of novel small molecule inhibitors of Epidermal Growth Factor Receptor (EGFR) designed for the treatment of EGFR-mutant lung cancers (Press release, SpringWorks Therapeutics, OCT 20, 2021, View Source [SID1234591670]). The portfolio, which was originally developed in the laboratory of Nathanael Gray, Ph.D., Professor of Chemical and Systems Biology, Co-Director of Cancer Drug Discovery, and Co-Leader of the Cancer Therapeutics Research Program at Stanford Medicine, includes several differentiated, first-in-class chemical series representing novel approaches to targeting mutant EGFR and is designed to address both de novo oncogenic drivers and emerging resistance mutations to existing EGFR inhibitors. The most advanced asset in the portfolio is currently in lead optimization and targets the C797S resistance mutation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are very pleased to expand our portfolio with the in-license of these selective and differentiated EGFR inhibitors, which are complementary to our strategy of developing novel targeted therapies for patients with biomarker-defined solid tumors," said Saqib Islam, Chief Executive Officer of SpringWorks. "In addition to the monotherapy opportunities in lung cancer, where a significant unmet medical need remains, these EGFR inhibitors provide several avenues for combination therapy development as well."

"Since our lab discovered the initial compounds that could address EGFR T790M mutations, we have been exploring additional strategies to create next-generation agents for patients with EGFR-mutant lung cancers in order to address the resistance mutations that inevitably arise upon treatment with osimertinib and other therapies," said Dr. Gray. "I am grateful for the SRA support from SpringWorks and continued collaboration with my former colleagues at Dana-Farber to further this exciting science with the goal of translating our initial discoveries into meaningful new therapies for cancer patients."

Under the terms of the license agreement, SpringWorks will provide Dana-Farber with an upfront payment and Dana-Farber will be eligible to receive development and commercial milestones and royalties based on any future net sales. Concurrent with this license, SpringWorks has entered a multi-year SRA to fund continued research and development in Dr. Gray’s laboratory at Stanford Medicine as well as collaborating laboratories at Dana-Farber, including those of Pasi Jänne, M.D., Ph.D., Director of the Lowe Center for Thoracic Oncology at Dana-Farber and Professor of Medicine at Harvard Medical School, Michael Eck, M.D., Ph.D., Professor of Biological Chemistry and Molecular Pharmacology at Dana-Farber and Harvard Medical School, and Jarrod Marto, Ph.D., Principal Investigator at Dana-Farber and Associate Professor of Pathology at Brigham and Women’s Hospital and Harvard Medical School. This SRA is intended to support lead optimization and translational biology efforts as the portfolio advances towards development candidate nomination.

"Drs. Gray, Jänne, Eck and Marto have been pioneers in the discovery and development of precision medicines for cancer patients. Through this license agreement and multi-year research collaboration, we have the opportunity to advance programs at the leading edge of targeted oncology development, potentially delivering first- and best-in-class medicines to address emerging drivers of therapeutic resistance," said Mike Burgess M.B.Ch.B., Ph.D., Head of Research & Development at SpringWorks.

On October 20, 2021 Point32Health and Takeda Pharmaceuticals America, Inc. reported that they have signed an innovative risk-sharing agreement around Takeda’s ALUNBRIG (brigatinib), a potent and selective tyrosine kinase inhibitor (TKI) that is approved for adult patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) as detected by an FDA-approved test (Press release, Takeda, OCT 20, 2021, View Source [SID1234594767]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The agreement will make ALUNBRIG broadly available to Point32Health’s more than two million members – with Takeda standing behind the medicine with a unique outcomes-based structure. The agreement is among the first risk-sharing contracts in oncology and the very first in ALK+NSCLC.

"Given the importance of facilitating cutting-edge oncology treatment and also the reality that not all patients show a positive response, reimbursement for oncology treatments is an area that is prime for innovative financing approaches," said Michael Sherman, MD, chief medical officer and executive vice president, Point32Health. "We’re excited to be able to demonstrate the value of ALUNBRIG as a treatment option for people with ALK+ NSCLC. Collaborating with Takeda to share risk makes this agreement a crucial milestone in bringing cost-effectiveness to cancer care."

"Takeda is committed to identifying and collaborating with payers on innovative and bold solutions that help ensure patients have access to our transformative therapeutics," said Dion Warren, vice president, head, U.S. Business Unit, Takeda Oncology. "Through this collaboration, Point32Health is able to allow broader access to ALUNBRIG because Takeda stands behind the value of its medicine and is willing to minimize the financial risk."

On October 20, 2021 Clovis Oncology, Inc. (NASDAQ: CLVS) reported that it will announce its third quarter 2021 financial results on Wednesday, November 3, 2021, before the open of the US financial markets (Press release, Clovis Oncology, OCT 20, 2021, View Source [SID1234591582]). Clovis’ senior management will host a conference call and live audio webcast at 8:30am ET to discuss the Company’s results in greater detail.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The conference call will be simultaneously webcast on the Clovis Oncology website www.clovisoncology.com, and a replay of the webcast will be available for 30 days.

Dial-in numbers for the conference call are as follows: US participants 888.440.4615, International participants 646.960.0682, conference ID: 2259685.

On October 20, 2021 Van Andel Institute’s Scott Rothbart, Ph.D., reported that it has earned a four-year, $792,000 Research Scholar’s Grant from the American Cancer Society to investigate the mechanisms that power a promising class of potent anti-cancer drugs (Press release, Van Andel Institute, OCT 20, 2021, View Source;utm_medium=rss&utm_campaign=american-cancer-society-grant-scott-rothbart [SID1234591602]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Scott Rothbart, Ph.D.

The drugs, called EZH2 inhibitors, work by targeting an enzyme called EZH2 that has long been of interest to cancer researchers because it interacts with the proteins that support DNA. As such, EZH2 plays a major role in switching genes that regulate cell proliferation "on" or "off" — a process that can lead to cancer if it goes awry. It also helps tumors evade attack by the immune system.

Because of their central role in all aspects of health and disease, proteins and the molecules that interact with them, such as EZH2, often are powerful targets for therapeutic development. Currently, several EZH2 inhibitors are undergoing clinical trials in cancer.

"EZH2 has immense potential to move the needle toward more targeted cancer treatments. We hope to contribute to this important work by defining the spectrum of molecules with which EZH2 interacts to help guide development of more precise therapeutic strategies," Rothbart said. "I am honored and humbled to receive this award from the American Cancer Society and look forward to uncovering new insights that may help improve treatment for people with cancer."

In 2018, Rothbart and his collaborators developed a new method to study lysine methyltransferases, the family of enzymes to which EZH2 belongs. Their work revealed that these important molecules interact with far more proteins than previously thought. Proteins are the molecular workhorses of the body and are responsible for carrying out all biological processes.

"We are proud to fund the innovative research by Dr. Scott Rothbart at Van Andel Institute, made possible by dedicated American Cancer Society supporters," said Kathy Goss, Ph.D., vice president of Regional Cancer Control at the American Cancer Society. "By investing in the research community’s brightest minds and best ideas, we continue to improve the lives of cancer patients and their families and, ultimately, move closer to a world without cancer."

Scott B. Rothbart, Ph.D., is supported by a Research Scholar Grant, RSG-21-031-01-DMC, from the American Cancer Society.